Organigram Global (OGI) Cash & Current Investments (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash & Current Investments of -$33.1 million for Q1 2026, up 31.53% year-on-year from -$25.1 million in Q1 2025, and up 1.88% on a QoQ basis from -$33.7 million in Q4 2025.
Organigram Global (OGI) Cash & Current Investments (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash & Current Investments for 9 consecutive years, with -$33.1 million the latest figure, recorded in Q1 2026.
- Quarterly Cash & Current Investments rose 31.53% year-over-year to -$33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.1 million (up 49.71% YoY) and the FY2025 annual result came in at -$33.7 million, changed N/A from the prior year.
- Cash & Current Investments rose to -$33.1 million in Q1 2026 per OGI's latest filing, from -$33.7 million in the prior quarter.
- Over the last five years, Cash & Current Investments for OGI reached as high as $97.2 million in Q3 2024 and fell as low as -$48.3 million in Q1 2025.
- A 5-year average of $5.6 million and a median of $1.7 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments jumped 151.78% — and 2025, when it sank 93.1%.
- Year by year, Cash & Current Investments stood at $20.8 million in 2022, then jumped by 85.38% to $38.6 million in 2023, then slumped by 145.22% to -$17.5 million in 2024, then plunged by 93.1% to -$33.7 million in 2025, then rose by 1.88% to -$33.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered -$33.1 million, -$33.7 million, and $21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Organigram Global | 121.15 Mn | 154.23 Mn | 28.97 Mn | -33.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.08 Mn |
| Dec 31, 2025 | -33.71 Mn |
| Sep 30, 2025 | 21.09 Mn |
| Mar 31, 2025 | -48.31 Mn |
| Dec 31, 2024 | -17.46 Mn |
| Sep 30, 2024 | 97.21 Mn |
| Sep 30, 2023 | 38.61 Mn |
| Aug 31, 2022 | 20.83 Mn |
| Nov 30, 2021 | 69.01 Mn |
| Aug 31, 2021 | 183.56 Mn |
| May 31, 2021 | 169.16 Mn |
| Feb 28, 2021 | 71.12 Mn |
| Nov 30, 2020 | 133.90 Mn |
| Aug 31, 2020 | 56.11 Mn |
| May 31, 2020 | 32.02 Mn |
| Feb 29, 2020 | 41.24 Mn |
| Aug 31, 2019 | 287,429.99 |
| Aug 31, 2018 | 55.06 Mn |